Tag Archives: Technology

Venn Life Sciences Puts LabSkin in the Game

Just think what Frankenstein could do with this product. It looks like skin, feels like skin, but it’s not skin. It’s LabSkin, a facsimile, being manufactured by a clinical research group Venn Life Sciences. Demand for replacement technologies stemmed from the European Union ban on selling cosmetics tested on animals in March 2013, proving where […]
Posted in Deals, R&D, Technology | Also tagged , , | Leave a comment

The Pulsing Pharmaceutical: Bioelectronics

GSK Lights a Spark around Bioelectronics Dominating the frontier of medicines discovery is a simple, endlessly challenging question: if not a drug, then what?  Industry science has evolved from the chemical roots of the small molecule to the biologics synthesized from living organisms, but the delivery mechanism – pill or injectable – is basically the […]
Posted in Global, R&D, Technology | Also tagged , , , | 1 Comment

Why the Smartwatch Should Make Time for Health

Smartwatches need health data to matter, writes Peter Houston. Still getting used to the idea of a smartphone? Better be quick, the smartwatch is on its way … or maybe not if iOS is your tech platform of choice. Despite usual whirl of rumours that accompany any major product announcement from Apple, the much imagined […]
Posted in Guest Blog, healthcare, Op-Ed, Technology | Also tagged , , , , , , , , | Leave a comment

How to Win in the Diabetes Space

Novo Nordisk’s SVP of national diabetes sales speaks with PharmExec about a new field force technology initiative, implications of the Sunshine Act, and why Victoza sales won’t slow down anytime soon. At a time when meaningful growth at most big pharma companies is happening in emerging markets – and nowhere else – Novo’s 2Q earnings […]
Posted in compliance, FDA, healthcare, leadership, patient education, People, Sales, Strategy, Technology | Also tagged , , , , , , , , | 5 Comments

FT Healthcare Conference: Society as Stakeholder

Speakers at the 2nd annual Financial Times US Healthcare and Life Sciences conference in New York last week discussed the cost of health, and the implications of an increasingly vocal and influential stakeholder group: the local populace. After opening remarks from Andrew Jack, FT’s prolific pharmaceuticals correspondent, Pfizer CEO Ian Read took the stage at […]
Posted in Europe, Events, Global, healthcare, leadership, Market Access, Orphan Drugs, People, pricing, R&D, Regulatory, Strategy, Technology | Also tagged , , , , , , , , , , , , , , , , | Leave a comment
  • Categories

  • Meta